Myelos Neurosciences Overview

  • Year Founded
  • 1994

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $35M

Myelos Neurosciences General Information

Description

Developer of therapeutics for neuropathic pain, peripheral neuropathy and neurodegenerative central nervous system disorders. The company provides peptide therapy to treat nervous system disorders and related degenerative diseases to treat pain syndromes and peripheral neuropathies.

Contact Information

Website
www.myelos.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 4940 Carroll Canyon Road
  • Suite M
  • San Diego, CA 92121
  • United States
+1 (619)
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 4940 Carroll Canyon Road
  • Suite M
  • San Diego, CA 92121
  • United States
+1 (619)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Myelos Neurosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 19-Mar-2001 $35M Completed Generating Revenue
1. Early Stage VC Completed Startup
To view Myelos Neurosciences’s complete valuation and funding history, request access »

Myelos Neurosciences Patents

Myelos Neurosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20100260734-A1 Method of stimulating prosaposin receptor activity Inactive 09-Mar-2001
US-7135461-B1 Having between 17 and 40 d-linked amino acids; improved proteolytic enzyme resistance; neurotrophic activity Inactive 16-Jun-2000
US-7109168-B1 Neurotrophic peptides exhibiting increased metabolic stability while retaining biological activity Inactive 16-Jun-2000
US-7115571-B1 Of given amino acid sequence; d-amino acid linkage makes peptides resistant to proteolytic degradation in vivo; same activity as native il-3 and also have neurotrophic activity Inactive 16-Jun-2000
US-7754688-B2 For promoting neurite outgrowth or myelination Inactive 16-Jun-1999 A61K38/10
To view Myelos Neurosciences’s complete patent history, request access »

Myelos Neurosciences Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Yellowstone Capital Partners PE/Buyout Minority
To view Myelos Neurosciences’s complete investors history, request access »

Myelos Neurosciences FAQs

  • When was Myelos Neurosciences founded?

    Myelos Neurosciences was founded in 1994.

  • Where is Myelos Neurosciences headquartered?

    Myelos Neurosciences is headquartered in San Diego, CA.

  • What industry is Myelos Neurosciences in?

    Myelos Neurosciences’s primary industry is Therapeutic Devices.

  • Is Myelos Neurosciences a private or public company?

    Myelos Neurosciences is a Private company.

  • What is the current valuation of Myelos Neurosciences?

    The current valuation of Myelos Neurosciences is .

  • What is Myelos Neurosciences’s current revenue?

    The current revenue for Myelos Neurosciences is .

  • Who are Myelos Neurosciences’s investors?

    Yellowstone Capital Partners has invested in Myelos Neurosciences.

  • When was Myelos Neurosciences acquired?

    Myelos Neurosciences was acquired on 19-Mar-2001.

  • Who acquired Myelos Neurosciences?

    Myelos Neurosciences was acquired by Savient Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process